Our Possibility
我們的可能性
研發專案
8
+
專利申請
150
+
進入臨床IND階段
最快
2.3
年
2024年的研發投資金額
7.89
億元
FBDB™
技術平台的核心優勢
結合先天性及適應性免疫系統 多管齊下攻擊腫瘤細胞
阻斷 SIRPα / CD47 訊號傳遞
阻斷 PD-1 / PD-L1訊號傳遞
改善腫瘤微環境或進一步激活巨噬細胞/T細胞
News
最新消息
漢康生技宣布取得 FDA Type C 會議正式紀錄，支持 HCB101 於二線胃癌／胃食管結合部癌之明確開發路徑 HanchorBio Announces FDA Type C Meeting Minutes Supporting a Clear Development Path for HCB101 in Second-Line Gastric/GEJ Cancer
HanchorBio announced receipt of the official minutes from its recent U.S. Food and Drug Administration (FDA) Type C meeting regarding the post-Phase 1 development strategy for HCB101.
6 月 30, 2026
Read more
漢康生技於 JCA-AACR 2026 發表 HCB101 胃癌及頭頸癌臨床數據，展現髓系免疫增強策略潛力 HanchorBio Showcases HCB101 Myeloid-Enhancer Strategy in Gastric Cancer and HNSCC at JCA-AACR 2026
HanchorBio, Inc. announced poster presentations of HCB101 clinical data at the 9th Japanese Cancer Association (JCA) and the American Association for Cancer Research (AACR) Special Joint Conference on Novel Therapies and Diagnostics in Upper Digestive and Head and Neck Cancers, taking place June 28-30, 2026, in Kyoto, Japan.
6 月 30, 2026
Read more
漢康生技受邀於 TRPMA 生技產業交流講座分享國際化發展經驗
HanchorBio Invited to Share International Expansion Experience at TRPMA Biotech Industry Exchange Forum.
6 月 22, 2026
Read more
漢康生技將出席 BIO 國際大會 2026，拓展全球合作交流機會 HanchorBio to Attend BIO International Convention 2026 to Advance Global Partnering Opportunities
HanchorBio today announced that Dr. Yuehua Cong, Chief Business Officer, will attend BIO International Convention 2026
6 月 19, 2026
Read more
漢康生技於2026 ESMO靶向抗癌治療亞洲大會發表兩場口頭報告，展現下一代免疫療法臨床進展 HanchorBio Presents Two Oral Presentations at ESMO TAT Asia 2026 Highlighting Progress Across Its Next-Generation Immunotherapy Pipeline
HanchorBio announced that two company-sponsored clinical programs were featured in oral presentations at the European Society for Medical Oncology Targeted Anticancer Therapies Asia Congress 2026, ESMO TAT Asia 2026, held in Hong Kong.
6 月 13, 2026
Read more
漢康生技於 FOCIS 2026 發表突破性數據，支持先天免疫產品引擎布局腫瘤與自體免疫疾病 HanchorBio Presents Late-Breaking Data at FOCIS 2026 Supporting Innate-Immune Product Engine Across Oncology and Autoimmune Disease
HanchorBio announced the presentation of late-breaking clinical and translational data at the Federation of Clinical Immunology Societies Annual Meeting, FOCIS 2026, being held June 9-12, 2026, in San Francisco.
6 月 10, 2026
Read more
漢康生技於 ASCO 2026 發表兩項摘要，展現 HCB101 聯合療法臨床活性與 HCB301 首次人體試驗進展 HanchorBio Presents Two ASCO 2026 Abstracts Highlighting HCB101 Combination Activity and HCB301 First-in-Human Clinical Progress
HanchorBio announced updated clinical data for HCB101 and HCB301 presented at the 2026 Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago.
6 月 01, 2026
Read more
漢康-KY將於5月29日創新板掛牌 HCB101臨床進展帶動國際合作布局 HanchorBio to List on Taiwan Innovation Board at NT$120 per Share as HCB101 Clinical Data Support Global Partnering Discussions
HanchorBio announced that it will be officially listed on the Taiwan Innovation Board on May 29, 2026, with an underwriting price of NT$120 per share.
5 月 28, 2026
Read more
漢康-KY引進國際策略投資人奧博資本入股 5月29日創新板掛牌 詢圈超額認購 HanchorBio Prices IPO at NT$120 Ahead of Innovation Board Listing on May 29
HanchorBio announced the completion of bookbuilding for its initial public offering on the Taiwan Innovation Board. The offering price has been set at NT$120 per share. HanchorBio is expected to list on the Taiwan Innovation Board on May 29, 2026.
5 月 26, 2026
Read more
首筆授權金挹注營收 漢康-KY聚焦2026年臨床與商務發展重點 推進HCB101臨床開發、創新板上市進程及國際合作布局 HanchorBio Reports First Licensing Revenue and Outlines 2026 Clinical and Business Development Priorities
HanchorBio today announced that its 2026 Annual General Meeting was successfully held on May 21, 2026, in Taipei, Taiwan. Shareholders approved all proposed resolutions, including the 2025 business report, financial statements, and loss offset proposal.
5 月 21, 2026
Read more
JOIN OUR TEAM
